- Home
- Solutions
- By Diseases
- Autoimmune Ophthalmic Diseases
- Corneal Hysteresis (CH)
Corneal hysteresis (CH) corresponds to the viscoelastic biomechanics of the cornea that defines its capacity to absorb and dissipate energy during a cyclic deformation. Protheragen offers comprehensive services to support the development of both diagnostic tools and therapeutic interventions related to Corneal Hysteresis (CH).
Corneal hysteresis (CH) describes the viscoelastic characteristic of the cornea that can absorb and dissipate energy, which is crucial for estimating the biomechanical properties of the cornea. It is defined as the difference in intraocular pressure (IOP) while a pulse of air inflates and deflates the cornea. As glaucoma becomes a public health concern, CH reflects the biomechanical properties of more posterior structures like the lamina cribrosa and peripapillary sclera. These scleral structures are thought to play a key role in the pathogenesis of glaucoma. Loss of CHs accompanies increased rigidity and reduced dampening capability of the cornea which might suggest increased vulnerability and hence facilitate development of glaucoma.
Fig.1 Corneal hysteresis (CH) is a surrogate marker for glaucoma. (Fung A. T., et al., 2023)The underlying mechanisms of corneal hysteresis (CH) in glaucoma, involve the biomechanics of the cornea and its radial interaction with intraocular pressure (IOP). The cornea, similar to other ocular components, displays both elastic and viscous behavior. Lower CH means diminutive hysteretic response of the cornea and is likely to occur due to posterior biomechanical alterations of the eye like the lamina cribrosa with peripapillary sclera too. Higher levels of IOP tend to corneal and scleral stiffness due to increased stress, leading to enhanced strain on the lamina cribrosa and subsequent injury to the optic nerve. Evidence shows that eyes with lower CH experience less displacement of the lamina cribrosa with a higher risk of glaucoma progression.
IOP-Lowering Therapies
Prostaglandin analogues (e.g., latanoprost) may transiently alter CH, though chronic use has shown mixed effects.
Biomechanical-Targeted Therapies
Experimental approaches aim to modulate corneal or scleral stiffness, though none are clinically approved.
Antioxidant Therapies
Investigational due to associations between oxidative stress and low corneal hysteresis (CH).
Protheragen recognizes that every research and development undertaking come with different associated needs, and thus, we provide customized therapeutics development services for our clients with particular requirements in the field of Corneal Hysteresis (CH).
Protheragen provides a suite of preclinical research services focused on Corneal Hysteresis (CH). This includes the characterization of CH in various animal models of ocular diseases, allowing for the assessment of how different conditions impact corneal biomechanics. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.